GlassScriptPhysician profile
Robert W Weaver
NPI 1578543799
$62,053.67
in general payments reported to CMS, 2019-2025
86 companies · $5,678 in 2025
The $5,678 reported for 2025 was more than what 75% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $11K · 2021: $12K · 2022: $2,911 · 2023: $9,409 · 2024: $4,233 · 2025: $5,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $6,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,270.19 |
| Consulting Fee | $6,050.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $17,691.39 | 2019-2025 | |
| Genentech USA, INC. | $9,159.27 | 2019-2025 | Tecentriq, Polivy, Alecensa |
| Immunomedics, INC. | $7,238.22 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $6,341.67 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $1,785.57 | 2019-2025 | Opdivo, Opdualag |
| Immunogen, INC. | $1,638.78 | 2023 | Elahere |
| Novartis Pharmaceuticals Corporation | $1,441.75 | 2019-2025 | |
| Celgene Corporation | $1,363.39 | 2019-2025 | Reblozyl, Pomalyst, Breyanzi |
| Pfizer INC. | $1,107.58 | 2019-2025 | |
| Daiichi Sankyo INC. | $1,105.86 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Gilead Sciences, INC. | $1,056.29 | 2019-2025 | Trodelvy |
| Lilly USA, LLC | $941.64 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $920.53 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| Rigel Pharmaceuticals, INC. | $642.04 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Incyte Corporation | $619.02 | 2019-2025 | Jakafi, Monjuvi, Jakafi |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $562.05 | 2019-2025 | |
| Exelixis INC. | $528.23 | 2019-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $515.82 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Tetraphase Pharmaceuticals, INC. | $455.25 | 2019-2020 | |
| Tersera Therapeutics LLC | $435.22 | 2021-2025 | Zoladex |
| Seagen INC. | $402.07 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Glaxosmithkline, LLC. | $370.19 | 2019-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $369.27 | 2022-2025 | Venclexta |
| Amgen INC. | $341.48 | 2019-2025 | Vectibix, Nplate, Blincyto |
| Syndax Pharmaceuticals, INC. | $294.40 | 2025 | Revuforj |
| Takeda Pharmaceuticals U.S.A., INC. | $272.74 | 2019-2025 | Fruzaqla, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $265.25 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $246.18 | 2019-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $221.43 | 2022-2024 | |
| Array Biopharma INC | $198.93 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Beigene USA, INC. | $196.35 | 2021-2025 | Brukinsa |
| Pharmaessentia USA Corporation | $193.53 | 2024-2025 | Besremi |
| Stemline Therapeutics INC. | $188.16 | 2021-2023 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $165.92 | 2021-2025 | Libtayo |
| Astellas Pharma US INC | $163.44 | 2019-2025 | Xospata, Vyloy, Padcev |
| Ipsen Biopharmaceuticals, INC | $160.67 | 2021-2024 | Somatuline Depot, Onivyde |
| Sobi, INC | $151.87 | 2022-2025 | |
| Mirati Therapeutics, INC. | $136.99 | 2023-2024 | Krazati |
| Sanofi US Services INC. | $131.90 | 2025 | |
| Paratek Pharmaceuticals, INC. | $123.84 | 2023 | Nuzyra |
| Tesaro, INC. | $122.12 | 2019 | |
| Teleflex LLC | $118.35 | 2024 | Urolift |
| Foundation Medicine, INC. | $113.07 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $108.91 | 2020 | |
| Puma Biotechnology, INC. | $104.07 | 2020-2023 | |
| Sirtex Medical INC | $95.84 | 2019-2022 | |
| Blueprint Medicines Corporation | $85.09 | 2023-2024 | Ayvakit |
| Aveo Pharmaceuticals, INC. | $79.58 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $64.51 | 2019 | |
| Emd Serono, INC. | $57.82 | 2020-2025 | |
| Csl Behring | $57.71 | 2021-2023 | Afstyla, Idelvion |
| G1 Therapeutics, INC. | $55.61 | 2023 | Cosela |
| Tg Therapeutics, INC. | $51.96 | 2022 | |
| Myriad Genetic Laboratories, INC. | $49.62 | 2022 | |
| Genentech, INC. | $47.92 | 2024 | |
| Aadi Bioscience, INC. | $47.37 | 2024 | Fyarro |
| Cti Biopharma Corp. | $46.23 | 2023 | Vonjo |
| Tempus Ai, INC | $45.21 | 2024 | Xt Cdx |
| Pharmacosmos Therapeutics INC. | $43.93 | 2024-2025 | Monoferric |
| Heron Therapeutics, INC. | $41.61 | 2019-2022 | |
| Medtronic, INC. | $35.50 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $31.05 | 2019 | |
| Karyopharm Therapeutics INC. | $29.96 | 2020-2024 | Xpovio |
| Taiho Oncology, INC. | $29.27 | 2023-2024 | |
| Geron Corporation | $28.33 | 2025 | Rytelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.41 | 2023 | Gilotrif |
| Beone Medicines USA, INC. | $24.81 | 2025 | Brukinsa |
| Epizyme, INC. | $22.37 | 2022 | |
| Corcept Therapeutics | $22.25 | 2025 | Korlym |
| Recordati_rare_diseases_inc. | $21.65 | 2024 | Sylvant |
| Secura Bio, INC. | $19.16 | 2020-2022 | |
| Deciphera Pharmaceuticals INC. | $18.28 | 2021 | |
| Progenics Pharmaceuticals, INC. | $16.71 | 2023 | Pylarify |
| Ge Healthcare | $16.30 | 2022 | |
| Agios Pharmaceuticals, INC. | $16.03 | 2023 | Pyrukynd |
| Morphosys, US INC. | $16.03 | 2023 | Monjuvi |
| Verastem, INC. | $15.55 | 2019 | |
| Sumitomo Pharma America, INC. | $14.80 | 2023 | Orgovyx |
| Kite Pharma, INC. | $14.29 | 2021 | |
| Acrotech Biopharma INC. | $14.25 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.16 | 2019 | |
| Adc Therapeutics America, INC. | $12.49 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $12.34 | 2019 | |
| Veracyte, INC. | $0.97 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Calquence $4,878Elahere $1,808Reblozyl $717Enhertu $669Tavalisse $642Rezlidhia $593Trodelvy $566Opdivo $521Verzenio $484Zoladex $421Lenvima $383Padcev $365Kisqali $347Tukysa $340Jakafi $334Keytruda $317Jaypirca $313Datroway $302Cabometyx $282Ayvakit $243Ibrance $223Ojjaara $212Braftovi $199Besremi $194Adcetris $187Vonjo $168Erleada $167Monjuvi $164Rybrevant $159Mektovi $156Revuforj $146Inlyta $142Tivdak $139Krazati $137Pomalyst $134Retevmo $131Imbruvica $130Sarclisa $125Nuzyra $124Libtayo $122Urolift $118Darzalex $116Gavreto $116Lorbrena $113Elrexfio $105Piqray $100Xospata $97.72Brukinsa $96.41Xtandi $93.26Pluvicto $93.02Lynparza $90.60Venclexta $88.58Fabhalta $87.97Zynyz $74.47Zepzelca $73.46Talzenna $68.59Jemperli $66.37Fruzaqla $60.42Carvykti $59.99Lutathera $58.64Alunbrig $57.95Cosela $55.61Imfinzi $54.32Vectibix $49.67Bosulif $49.06Fyarro $47.37Orserdu $46.17Tecentriq $45.51Xt Cdx $45.21Talvey $44.77Monoferric $43.93Tecvayli $43.00Opdualag $42.90Fotivda $41.45Promacta $40.79Comirnaty $39.12Nplate $37.78Somatuline Depot $35.67Onivyde $35.67Paxlovid $33.74Welireg $31.98Breyanzi $31.56Orgovyx $30.06Jevtana $29.32Lonsurf $29.27Inqovi $29.27Pemazyre $28.35Rytelo $28.33Enjaymo $27.48Gilotrif $27.41Polivy $26.72Nubeqa $26.10Xofigo $26.10Injectafer $22.75Korlym $22.25Scemblix $21.94Sylvant $21.65Vyloy $20.77Xalkori $20.70Blincyto $20.64
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.